NEW YORK, Jan. 16-Atugen has secured a license to Isis Pharmaceuticals' antisense-based functional genomics techniques, the two companies said today.
Atugen, which has its own functional genomics technology to reduce expression in selected genes, will be able to use Isis' techniques for discovery and validation of both targets and compounds for itself and for its customers.
Isis' functional genomics technologies, held by its GeneTrove division, include antisense inhibitors that work through RNAse H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.
The deal complements Atugen's existing services in siRNA, transfection and gene expression reduction, the Berlin-based company said in a statement. Atugen has obtained licenses from various companies for antisense and RNA interference technologies.
Isis Pharmaceuticals is based in Carlsbad, Calif. It is a public company.